Cefiderocol Matches Standard Care in Gram-Negative Bloodstream Infection

The first randomised trial dedicated to cefiderocol for hospital-acquired and health-care-associated Gram-negative bloodstream infection shows non-inferiority but no superiority, with a concerning mortality signal in metallo-beta-lactamase producers.

📅 Journal publication: Feb 2026 (online Oct 6, 2025) · Last updated: Jul 30, 2026

cefiderocolsiderophore cephalosporinGram-negative bloodstream infectioncarbapenem-resistant organismsmetallo-beta-lactamaseEnterobacteralesAcinetobacternon-inferiority trialantimicrobial resistanceIDSAstewardship Infectious Disease / Antimicrobials

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Paterson DL, Sulaiman H, Liu PY, Chatfield MD, Yilmaz M, Salmuna ZN, Mazlan MZ, Anunnatsiri S, Sirijatuphat R, Chotiprasitsakul D, Lye DC, Somani J, Kalimuddin S, Aslan AT, Thamlikitkul V, Lee YT, Yang YS, Lin YT, Ramli WNW, Tseng CH, Archuleta S, Chan YFZ, Forde BM, Wright H, Stewart AG, Ramsay KA, Ling W, Rossi V, Harris-Brown TM, Harris PNA, GAME CHANGER Trial Investigators

Citation: Paterson DL, Sulaiman H, Liu PY, et al. Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial. The Lancet. Infectious diseases. 2026;26(2):148-159. doi:10.1016/S1473-3099(25)00469-4

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.